Determination of the underlying cause of death in three multicenter international HIV clinical trials.
about
Purinergic Receptors: Key Mediators of HIV-1 Infection and InflammationInflammatory and coagulation biomarkers and mortality in patients with HIV infectionMonitoring linked epidemics: the case of tuberculosis and HIV.Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment programActivation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.T cell subsets in HIV infected patients after successful combination antiretroviral therapy: impact on survival after 12 years.Biomarkers of immune dysfunction in HIV.Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy studyRelationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals.Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals.Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.Thromboelastography on plasma reveals delayed clot formation and accelerated clot lyses in HIV-1 infected persons compared with healthy controlsCirculating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control StudyElectrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study)Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental deathImpact of Depression and Inflammation on the Progression of HIV Disease.The role of HIV in serious diseases other than AIDS.Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United StatesClinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: a systematic review.HIV infection and mental health: suicidal behaviour--systematic review.Considerations for Endpoint Selection When Designing HIV Clinical Trials.Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals.Use of the Coding Causes of Death in HIV in the classification of deaths in Northeastern Brazil.Inflammation Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It?High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort.Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trialSepsis: Personalized Medicine Utilizing 'Omic' Technologies-A Paradigm Shift?
P2860
Q26774666-B394BB78-E851-489F-A9D4-3CC59193F833Q28473903-C831B2C7-210F-4A5E-9171-A4947E4DE99AQ33526343-F2F1BE0E-2219-49EB-A939-DECE06E48B22Q33727282-DD77E59B-4EE3-47AA-B9AF-96A0D56753F7Q33943429-701465E6-0D31-4DA0-ACF1-5CDD7B2026AAQ33962303-EBBF4674-2F83-4A1D-9DE8-0AEFF23374D8Q33987654-F5526BBE-812B-49B6-AA89-54DF63B9E077Q34344703-670934DF-566F-4506-8BC3-AD365F5A38C0Q34546742-B835D99B-332A-4F64-BA0A-687701147367Q34694448-AB632715-207C-49F4-9330-834009623376Q34781765-EB35E8D5-2AF6-4300-A5CA-656535C67F29Q34831090-75650285-C0AB-4E31-9CD3-49DF785E8622Q35030752-B9C585FD-390C-4969-BF73-5244EE3F597AQ35146687-DDD804D0-F541-439B-B989-995A869D4A58Q35785698-1CC7E8C5-869A-4E4D-A2D5-7FE364249BA5Q35806035-CE4590CF-F45C-4CAF-8367-271D3AE18488Q36476523-E678AA27-DFF8-439F-9F31-D13F27881981Q36956948-4F6B2CEA-3FA6-410B-88C1-42D5FF48F981Q37138606-CB87DB0E-FB24-4F3D-B070-D42B159CAF17Q37186467-300E7A11-9D06-433A-81BD-0347E2DE8DDFQ37272859-7AE3B453-7F32-4B7D-9DCB-9AF97B295C1EQ37713159-0C3EFDD9-9785-4703-AA56-19F5377546E4Q37899892-B175951E-32AA-4DAD-A0D1-F341AD6C64FAQ37967498-6BCA6D2B-C066-4B18-8D1F-B9216EE18219Q40061540-986D1D85-490D-4728-8356-4EB5A3C45EEEQ41703460-64A8AF1F-E2FA-437D-AABB-8F0A47D3A8ABQ41989633-9EC6FD21-4CAC-467B-9242-E402EE623D0DQ42207980-3140FF28-CE56-4B9F-AEE5-C1DA09856C37Q58000817-54F78D05-BC2D-4C35-A0C6-914AFB9BBA65Q58758376-595C390B-4923-4D55-94A7-82E198A496A7
P2860
Determination of the underlying cause of death in three multicenter international HIV clinical trials.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Determination of the underlyin ...... rnational HIV clinical trials.
@ast
Determination of the underlyin ...... rnational HIV clinical trials.
@en
type
label
Determination of the underlyin ...... rnational HIV clinical trials.
@ast
Determination of the underlyin ...... rnational HIV clinical trials.
@en
prefLabel
Determination of the underlyin ...... rnational HIV clinical trials.
@ast
Determination of the underlyin ...... rnational HIV clinical trials.
@en
P2093
P2860
P356
P1433
P1476
Determination of the underlyin ...... ernational HIV clinical trials
@en
P2093
Alan R Lifson
Cate Carey
Court Pedersen
Daniel Duprez
Daniel E Nixon
Daniela C Gey
Eric A Krum
Frank S Rhame
George Perez
INSIGHT Cause of Death Writing Group
P2860
P304
P356
10.1310/HCT0903-177
P577
2008-05-01T00:00:00Z